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Abstract
Background: Two anaesthetic machines, the “Primus
®” and the “Zeus
®” (Draeger AG, Lübeck, Germany), were
subjected to a cost analysis by evaluating the various expenses that go into using each machine.
Methods: These expenses included the acquisition, maintenance, training and device-specific accessory costs. In
addition, oxygen, medical air and volatile anaesthetic consumption were determined for each machine.
Results: Anaesthesia duration was 278 ± 140 and 208 ± 112 minutes in the Primus
® and the Zeus
®, respectively.
The purchase cost was €3.28 and €4.58 per hour of operation in the Primus
® and the Zeus
®, respectively. The
maintenance cost was €0.90 and €1.20 per hour of operation in the Primus
® and the Zeus
®, respectively. We
found that the O2 cost was €0.015 ± 0.013 and €0.056 ± 0.121 per hour of operation in the Primus
® and the
Zeus
®, respectively. The medical air cost was €0.005 ± 0.003 and €0.016 ± 0.027 per hour of operation in the
Primus
® and the Zeus
®, respectively. The volatile anaesthetic cost was €2.40 ± 2.40 and €4.80 ± 4.80 per hour of
operation in the Primus
® and the Zeus
®, respectively.
Conclusion: This study showed that the “Zeus
®” generates a higher cost per hour of operation compared to the
“Primus
®”.
Background
Statutory funding changes in health care systems place
hospitals under increasing cost pressures. Hospitals are
encouraged to work more efficiently, reduce costs and
adjust treatment protocols to secure their economic sur-
vival, which is essential in every healthcare system. The
use of investment and cost-intensive medical and tech-
nical equipment in hospitals is discussed in terms of
cost and profitability below. As the cost reduction in
hospitals is a major objective, we conducted a cost ana-
lysis of two anaesthetic machines, the “Primus
®” and the
“Zeus
®”. Both of these machines are manufactured by
Draeger. The “Primus
®” anaesthetic machine allows for
low-flow anaesthesia withf r e s hg a sf l o wr a t e s<1L /
min. In addition to a manually controlled fresh-gas con-
trol, the “Zeus” has automatic oxygen control, medical
air and volatile anaesthetics in a closed breathing sys-
tem. The reason for having automatic control is to
minimise the consumption of these gases, thus reducing
the cost of anaesthesia during a surgical procedure. The
aim of this study was to compare the “automatic”
approach of the Zeus
® to the more typical operator-
controlled method of the Primus
® and to investigate the
financial implications of using these different anaesthetic
machines in a clinical setting.
Methods
The ethics committee of the University Hospital Goet-
tingen (UMG) approved this study. We analysed the
cost of two anaesthetic machines ("Primus
®” vs.
“Zeus
®”, Draeger AG, Lübeck, Germany). These anaes-
thetic machines use different types of fresh-gas control
and were evaluated during surgery under general anaes-
thesia at the University of Goettingen. General anaesthe-
sia (GA) in the “Zeus
®” group was conducted with the
“Zeus” (Draeger AG, Lübeck, Germany) anaesthetic
machine. The “Primus
®” g r o u pu s e dt h e“Primus
®”
(Draeger AG, Lübeck, Germany) anaesthetic machine.
The “Primus
®” anaesthetic machine allows for low-flow
anaesthesia with fresh gas flow rates < 1 L/min. In
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the “Zeus
®” has automatic oxygen control, medical air
and volatile anaesthetics in a closed breathing system.
A total of 30 patients were included in this study and
all were American Society of Anaesthetists (ASA) classi-
fication I-III. All the patients were also undergoing
major cardiac or general surgery. Thirty patients were
evenly randomised into either the “Zeus
®” or “Primus
®”
group. Before the start of the study, the anaesthetic ven-
tilators and circuits were checked with the manufac-
turer’s recommended predetermined self-test. The
maximum allowed measured leakage was limited to 25
ml. Oxygen and medical air consumption was calculated
based on anaesthetic time. Connection of the patient to
the anaesthetic machine was defined as the time period
between the start time and the removal of the patient
from the machine, which was defined as the end time.
The induction phase was excluded from the study
because it was performed with other anaesthetic
machines in the anaesthetic room. The prices for the
gas and vapour supplies of the studied devices were
taken from our in-house pharmacies and equipment
cost lists, and the prices for device-specific parts were
taken from the Draeger price list. To calculate the
hourly values for the anaesthetic machines, an annual
workload of 1,920 h was calculated from equipment use
of 8 h per day, 20 days per month.
Anaesthesia
The specific anaesthesia protocol for each patient was
determined by the anaesthetist overseeing the case.
However, established clinical standards were always fol-
lowed. After the patients were premedicated with 0.1
mg/kg of Midazolam (Dormicum
®,R o c h e ,B a s e l ,S w i t -
zerland) in the morning and evening, the induction of
anaesthesia was performed intravenously with 2 μg/kg
of Sufentanil (Janssen-Cilag, Neuss, Germany) and, if
necessary, 0.3 mg/kg of Etomidate (Janssen-Cilag, Neuss,
Germany) until the eyelash reflex was lost. Then, the
patients were given 0.1 mg/kg of Pancuronium (Cur-
amed Schwabe, Karlsruhe, Germany), followed by oro-
tracheal intubation. Balanced anaesthesia was
maintained with 1% Sevoflurane (Abbott, Wiesbaden,
Germany) or 0.8% Isoflurane (Abbott, Wiesbaden, Ger-
many), supplemented with a continuous infusion of an
opioid (1 μg/kg/min of Sufentanil) during cardiac sur-
gery and intermittent administration of an opioid (0.2
μg/kg of sufentanil) during general surgery [1]. In the
general surgery cases, general anaesthesia was combined
with a thoracic epidural. The mechanical ventilation was
adjusted to achieve an end-tidal carbon dioxide (CO2)
concentration of 35 mmHg and an oxygen saturation of
95%. This was achieved by adjusting the fraction of
inspired oxygen and the positive end-expiratory pressure
(PEEP). In the “Zeus
®” group, the ventilator was used in
the closed mode (auto control). In the “Primus
®” group,
the anaesthetist in charge was free to choose his or her
dosage mode (high flow, low flow or minimal flow). Our
clinical standards recommend that after an initial wash
in phase with 4 l/min of fresh gas flow, a low-flow
anaesthesia, with a fresh gas flow rate < 1 l/min, is used
after reaching the desired steady state concentration of
the volatile anaesthetic [2-4].
Statistics
The statistical calculations were performed with the Sta-
t i s t i c as o f t w a r e( S t a t s o f tI n c . ,T u l s a ,O K ,U S A ) .F o ra l l
the analytical methods, a p < 0.05 for alpha errors was
considered significant. To determine if the results had a
normal distribution, a Kolmogorov-Smirnov test was
performed. Upon confirming a normal distribution, the
results were expressed as the mean ± standard deviation.
A paired Student’s t-test was used to evaluate significant
differences between paired samples, and an unpaired
Student’s t-test was used to evaluate differences between
independent samples. In cases where the data were not
normally distributed according to the Kolmogorov-Smir-
nov test, the results were presented as a median and a
range. The test used to evaluate significant differences
in the paired samples when the data were not normally
distributed was the Wilcoxon matched-pairs test. For
the independent samples that were not normally distrib-
uted, the Mann-Whitney U test was used.
Results
The patient population did not differ in age, height,
weight or operating time. No differences were observed
with respect to volatile anaesthetics or the use of a thor-
acic epidural. In the “Primus
®” group 13 patients
received sevoflurane, and 2 patients received isoflurane.
In the “Zeus
®” group, 11 patients received sevoflurane,
and 4 patients received isoflurane. A thoracic epidural
was only used in the “Primus
®” group (n = 2). All the
cost comparison results related to anaesthesia for the
“Primus
®” and the “Zeus
®” are summarised in Tables 1,
2, 3.
Cost
The studied anaesthetic machines, the “Primus
®” and
the “Zeus
®”, depreciate on a straight-line basis over a 10
year period in the UMG. Straight-line depreciation
means that the cost of the depreciable asset will be
divided equally among the years of its useful life. Eur-
opean list prices were used to reference the acquisition
costs of the studied anaesthetic machines. Furthermore,
maintenance expenditures were considered, which are
necessary to maintain the anaesthetic devices in an
operational state.
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Page 2 of 8Table 1 Summary of maintenance costs for the “Primus
®” and the “Zeus
®”
Cost Primus
® (€) Zeus
® (€)
Maintenance 1 time/year (Draeger) 1000.90 1379.00
Maintenance 1 time/year
(in-house)
420 420
(120 + 300 spare parts) (120 + 300 spare parts)
Vaporiser Maintenance 188 523.28
1 time/year (Draeger) (94 × 2 Vaporisers) (130.82 × 2 DIVA modules and 2 maintenance checks/year)
Vaporiser Maintenance 144 NA
1 time/year (in-house) (72 × 2 Vaporisers)
Total cost 1752.90 2322.28
Table 2 Cost comparison of two anaesthetic machines: “Primus
®” and “Zeus
®”
Primus
® Zeus
® p-value
Age [years] 60 ± 19.6 72 ± 9.5 n.s.
Weight [kg] 80 ± 29.9 80 ± 29.4 n.s
Height [cm] 164 ± 30.8 163 ± 26 n.s
Purchase Costs [€] 62.894.01 88.056.43
Minutes of operation [hour]/year 1,920 1,920
Cost [€/hr of operation] 3.28 4.58
Maintenance Draeger [€/year] 1.000.90 1.379.00
Maintenance in-house [€/year] 420 420
Draeger Vaporiser Maintenance [€/year] 188.00 523.28
Vaporiser - in house maintenance [€/year] 144.00
Maintenance [€/hr) 0.90 1.20
Anaesthesia duration [minutes] 278 ± 140 208 ± 112 0.14
O2-consumption [m
3/anaesthesia] 0.1468 ± 0.0846 0.233 ± 0.180
O2-costs [€/anaesthesia] 0.0540 ± 0.030 0.086 ± 0.066
O2-costs [€/hr] 0.015 ± 0.013 0.056 ± 0.121 < 0.05
Medical air-Consumption [m
3/anaesthesia] 0.0546 ± 0.0377 0.0925 ± 0.06892
Medical air-cost [€/anaesthesia] 0.02020 ± 0.01347 0.03144 ± 0.02264
Medical air-cost [€/hr] 0.005 ± 0.003 0.016 ± 0.027 < 0.05
Volatile anaesthetic [ml/anaesthesia] 18.26 ± 9.71 27.10 ± 29.15
Volatile anaesthetic [€/anaesthesia] 10.09 ± 6.43 9.67 ± 6.56
Volatile anaesthetic [€/hr] 2.40 ± 2.40 4.80 ± 4.80 < 0.05
CO2-Absorber [€/hr] 1.36 1.36
IBF-Filter [€/hr] 0.25
Electricity cost [€/hr] 0.024 0.048
Rent for an OP theatre [€/hr] 12.00 12.00
Surface disinfection [€/anaesthesia] 0.15 0.15
Consumable costs [€/anaesthesia] 17.03 17.03
Training on equipment [€/hr] 0.54 0.54
Cost of an anaesthetist [€/hr] 42.00 42.00
Cost of an ODP [€/hr] 27.00 27.00
Cost of a medical technician [€/hr] 24.00 24.00
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®”, the acquisition cost was
€62,894.01. Taking into account the 10 years of depre-
ciation, the annual utilisation rate per hour was €3.28
for the “Primus
®”. The acquisition cost of the “Zeus
®”
was €88,056.43. Taking into account the 10 year depre-
ciation period, the annual utilisation rate for the
“Zeus
®” was €4.58 per hour.
Costs for device-specific accessories
The machines examined in this study required CO2
absorber cartridges (Draegersorb Clic 800 Plus, Draeger,
Luebeck, Germany). These absorber cartridges were
changed, on average, twice per week at a cost of €25
each. This led to an increase in operational cost of €1.36
per hour for the 1,920 h of service per year. The
“Zeus
®” anaesthetic machine required an additional IBF
filter used in conjunction with the absorber cartridge.
The IBF filters were changed twice per week, according
to recommendations from Draeger, at a cost of €4.59
each. The annual cost of the filters used was €477.36,
yielding costs of €0.25/h for the “Zeus
®”.
Maintenance costs
The Medical Devices Act (MPG), the Medical Devices
Operator Ordinance and proprietary inspection and
maintenance regulations specify at what interval and how
anaesthesia equipment must be checked. A maintenance
contract exists between UMG and Draeger with alternat-
ing tasks. Draeger and the in-house Medical Technical
Service (MTS) alternate performing the maintenance and
safety checks once a year. This contract covers the main-
tenance costs of the devices, which were set at fixed
prices for the 10-year period. These fixed amounts
include staff costs from Draeger and spare parts costs.
The replacement of specific parts is included in an
annual service package. Therefore, these parts are always
replaced, regardless of whether or not they show signs of
wear. In-house MTS maintenance costs include medical
technician costs. Because in-house maintenance cannot
predict which parts need to be replaced, an amount of
€300 was included based on experience in recent years.
Table 1 shows the composition of the maintenance
costs for the “Zeus
®” and “Primus
®” anaesthetic
machines.
“Primus
®”
For the “Primus
®”, a maintenance cost of €1,752.90/year
was determined, which included the Draeger costs
(€1,000.90) in addition to in-house maintenance costs
(€120 per year). The cost of in-house maintenance was
calculated from the hourly wage of a medical technician
(€24 per hour) and the service time for the “Primus
®”
(approximately 5 h per year). Furthermore, a calculated
cost of €300 for spare parts was expected. In addition to
servicing the anaesthetic machine, the anaesthetic
vaporisers are serviced separately. Because the “Pri-
mus
®” operates with two anaesthetic vaporisers, the
maintenance costs were doubled. The annual fixed
maintenance cost for the vaporisers from Draeger was
€94. The cost of in-house maintenance of the anaesthe-
sia vaporisers was €72 per vaporiser. This €72 includes
the hourly wage of a medical technician (€24/h) and a
3-hour maintenance period. Thus, the Primus
® service
cost was €0.90/h in total.
“Zeus
®”
The total maintenance costs for the “Zeus
®” were
€2,322.28 per year. This amount comprised fixed costs
by Draeger (€1,379), the cost of in-house maintenance
(€120) and the calculated value for spare parts (€300).
The “Zeus
®” uses a vaporiser system called DIVA mod-
ules, which are special anaesthetic injection systems
maintained exclusively by Draeger. The cost of main-
taining a DIVA module by Draeger was €130.82 each
and €523.28 per year. In total, the service cost for the
“Zeus
®” was €1.20/h.
Energy costs
Energy cost is the electricity used to operate the equip-
ment. Because a power consumption counter cannot be
Table 3 Cost comparison of two anaesthetic examples of
similar duration with the “Primus
®” and the “Zeus
®”
Anaesthesia costs Primus
® (€) Zeus
® (€)
Example anaesthetic
Duration of anaesthesia [min] 120 116
Consumption v. A. [ml] 15.69 51.11
Air consumption [m
3] 0.10 0.27
O2 consumption [m
3] 0.03 0.16
Cost Elements
Depreciation 6.55 8.87
Maintenance costs 1.83 2.33
Absorber cartridge costs 2.71 2.62
Cost filter for Zeus
® 0.48
Electricity 0.05 0.09
Cost of anaesthetist 84.00 81.20
Cost of an ODP 54.00 52.20
Consumable costs 17.03 17.03
Disinfection 0.15 0.15
Medical air 0.04 0.10
O2 0.01 0.06
Sevoflurane anaesthesia costs 9.27 30.19
Costs of training 1.08 1.05
Costs of rent 24.48 23.66
Total cost [€/Example anaesthetic] 201.19 220.03
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for patient safety reasons, the power consumption of the
anaesthetic machine was measured using a test lung. To
calculate the electricity cost, a running time of 1,920 h/
year was used. The “Primus
®"electricity consumption
was 130 W. At a price (as of May 2008) of 18.38 cents/
k W h ,t h ee n e r g yc o s tf o rt h e“Primus
®” was calculated
as €45.87 per year and €0.024 per hour. The “Zeus
®”
anaesthetic machine had a power consumption of 260
W. The electricity costs were €91.75 per year and
€0.048 per hour for the “Zeus
®”.
Cost of oxygen, medical air and volatile anaesthetics
Oxygen was delivered as a liquid (Air Liquide, Germany)
and made available through a gas pipeline system to the
entire University Hospital. The gaseous oxygen (€89.726
for 260,000 cubic meters of oxygen) yielded a cost of
€0.37/m
3, plus a maintenance cost of €5,712 per year.
Medical air was produced by an in-house compressor
and was provided through a medical gas pipeline. We
were unable to determine the hospital’s consumption of
medical air and therefore set the price as identical to
that of oxygen. Respective oxygen and medical air con-
sumption was determined from the anaesthetic
machines. Pre- and post-operative weighing of the
anaesthetic vaporisers, on a precision balance (Sartorius,
Sarorius, Göttingen, Germany), determined the con-
sumption of the volatile anaesthetics. Consumption was
calculated by dividing the difference in weight by the
physical density of the anaesthetic. The physical density
for sevoflurane and isoflurane is 1.53 g/ml and 1.50 g/
ml, respectively. For 250 mls of sevoflurane and isoflur-
ane, the cost is €147.67 and €31.10, respectively. This
makes the final cost €0.5907/ml for Sevoflurane and
€0.1244/ml for Isoflurane.
“Primus
®”
For the “Primus
®”, the average oxygen consumption was
0.147 ± 0.085 m
3 per anaesthesia, costing €0.054 ±
0.030. The average cost per minute for oxygen con-
sumption was €0.015 ± 0.013/h. The average consump-
tion of medical air per anaesthesia was 0.055 ± 0.036
m
3,c o s t i n g€0.020 ± 0.013. The cost per minute for
medical air was €0.005 ± 0.003 per hour. The average
consumption of volatile anaesthetics with the “Primus
®”
was 18.26 ± 9.71 ml per anaesthetic episode. This
means that the average costs were €10.09 ± 6.43 per
anaesthetic episode and €2.40 ± 2.40/h.
“Zeus
®”
The average oxygen consumption during anaesthesia
with the “Zeus
®” ranged between 0.233 ± 0.180 m
3,
costing €0.086 ± 0.066. Oxygen consumption for the
“Zeus” costs €0.056 ± 0.121/h. The average air
consumption with the “Zeus
®” was 0.092 ± 0.069 m
3
per anaesthetic episode, and the average costs were
€0.031 ± 0.023 per anaesthetic episode. The average cost
per minute of air consumption amounted to €0.016 ±
0.027/h.
Costs for surface cleaning of the anaesthetic machine
The surface disinfection of the equipment costs €0.15
per anaesthetic episode. This was calculated for a pack
of disinfectant wipes containing 200 towels, which costs
€10, assuming 3 cloths were used per cleaning.
Training costs for the studied anaesthetic machines
For patient safety, it is necessary that all operators are
knowledgeable about operating medical devices. The
German legislature (MPBetreibV) stipulates that only
personnel trained in the professional handling of medi-
cal devices are allowed to treat patients. Consequently,
doctors, ODPs (operation department personal, called
“anaesthetic nurses” in Germany) and nurses undergo
regular in-hospital education on the handling of medical
devices. The training is conducted and documented
according to German legislature guidelines (§ 7 MPBe-
treibV) in the medical products directory for medical
devices. For the hospital training costs, a flat rate of
€60/h per teacher was used. For this study, a briefing
time of 2 h for equipment training was assumed. Thus,
for the lecturers, a total of €120 was calculated. To facil-
itate this training, the expenditure on telephone calls,
equipment and room rent and other follow-up proce-
dures for the event was assumed to be €200. In addition,
during the time of training, staff costs for the participat-
ing anaesthetists and ODPs were considered. At an in-
house training, six doctors and four nurses participated
on average. The expense ratio is €42/h for an anaesthe-
tist and €27/h for an ODP. The personnel costs thus
totalled €720. The total cost of the equipment training
amounted to €1,040 in total and €54/h.
Costs for consumables
The cost of supplies used in this study consisted of a
breathing circuit (€3.71), an endotracheal tube (€7.65),
an HME-filter (€2.40) and a gas sampling line (€3.23).
The ventilation system and the gas sample line were
c h a n g e de v e r yd a ya n dt h et u b ea n dt h eH M Ef i l t e r s
were changed between every patient. The supplies listed
were used equally with both anaesthetic machines.
Thus, the supply costs in this study were €16.99 per
anaesthetic episode.
Staffing costs for the anaesthetist
The 2008 budget for anaesthetists amounted to
€5,499,450. This included social and health security,
holiday pay and on-call commitment costs for 59.5 full-
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week. The annual working time of any staff group was
calculated as follows: The standard hourly working time
multiplied by 52 weeks per year. An anaesthetist there-
fore works 2,184 h per year, at a cost of €42 per hour.
Staff ODP
Staffing costs per hour for the ODPs and medical tech-
nicians were calculated, which were €27 per hour for
the ODPs and €24 per minute for the medical
technicians.
Discussion and Conclusions
Given the pressure on hospitals to decrease their costs,
this work aimed to develop a methodology for compar-
ing two anaesthetic machines ("Primus
®” and “Zeus
®”).
In addition, the running costs of different fresh gas
delivery modes were evaluated using a cost analysis.
The “Primus
®” is able to use low-flow anaesthesia
while the “Zeus
®” utilises a quasi-closed automatic
breathing circuit. The cost analysis has shown that the
“Zeus
®”, with its automatic mode, was more expensive
with respect to fresh gas and volatile anaesthetic con-
sumption compared to manual metering with the “Pri-
mus
®”. Additionally, with respect to the cost of
acquisition and maintenance, the “Zeus
®” proved more
costly than the “Primus
®”.
In addition to cost, the contribution of volatile anaes-
thetics to the destruction of the stratospheric ozone
layer is of increasing importance, even if their effect on
global warming is currently considered very low [5].
The cost of implementing and sustaining an anaes-
thetic service with inhalational anaesthesia using an
anaesthetic machine can be divided into personnel costs,
acquisition costs for the anaesthetic machine, mainte-
nance costs, operating expenses, medical gases and vola-
tile anaesthetic costs. The overwhelming majority of the
expenses are staff costs [6]. The costs of the volatile
anaesthetics are dependent on four factors:
(1) The cost per millilitre of liquid volatile anaesthetic
(2) The gaseous volume of the liquid from each milli-
litre of volatile anaesthetic
(3) The clinical potency of the volatile anaesthetic
defined by the MAC value
(4) The anaesthetic machine selected fresh gas flow
A high fresh gas flow rate ("non-rebreathing system”)
prevents the rebreathing of anaesthetic gases and makes
the control of the agent’s concentration the simplest.
However, this produces the highest costs due to wasted
gases [7]. The economic benefits of low-flow anaesthesia
are controversial [8,9]. Studies evaluating the cost effec-
tiveness of anaesthetic machines most often look only at
the consumption of fresh gases and volatile anaesthetics
[10]. Although the costs of medical gases are only a
small fraction of the total operational costs, it is still
important to be aware of these costs. Aside from the
cost of medical gases, it is also important to appreciate
the costs incurred when using the anaesthetic machine
and the dispensing mode in addition to the acquisition
and maintenance costs.
Comparing acquisition and maintenance costs proved
the “Zeus
®” to be more costly than the “Primus
®”.A t
first glance, the increased purchase and maintenance
costs are not surprising. The Zeus
® is an anaesthetic
machine with the latest generation of technology. How-
ever, it is surprising that the quasi-closed automatic dis-
pensing mode of the “Zeus
®” is responsible for higher
anaesthetic gas costs compared to the low-flow anaes-
thesia of the “Primus
®”.
The “Primus
®” and the “Zeus
®” differ in their fresh
gas flow rates. Both the “Primus
®” and the “Zeus
®” have
manual oxygen control, medical air and volatile anaes-
thetics to provide all types of fresh gas dosages (minimal
flow, low flow and high-flow). The Zeus
® also offers an
additional automatic control (TCATM = Target Con-
trolled Anaesthesia) of oxygen, medical air and volatile
anaesthetics in a quasi-closed breathing system, with the
objective of minimising the consumption of fresh gases
and volatile anaesthetics. The cost analysis of the “Pri-
mus
®” and “Zeus
®” anaesthetic machines has shown
that the “Zeus
®”, in an automatic metering mode, was
more wasteful compared to the manual metering mode
of the “Primus
®”.A tf i r s tg l a n c e ,t h i si ss u r p r i s i n g .I t
w a se x p e c t e dt h a tt h e“Zeus
®” would use less fresh gas
and volatile anaesthetic because of its quasi-closed sys-
tem. Even in the low flow mode, the anaesthesia
machine would deliver surplus fresh gas and anaesthetic
into the breathing circuit. This effect is based on the
fresh gas control system in the “Zeus
®” anaesthetic
machine.
Because of the automatic control of fresh gas and
volatile anaesthetic flow, a change in the concentration
of volatile anaesthetic in the circle system was achieved
utilising maximum fresh gas flow rates of oxygen and/or
compressed air. This means that during these rapid
adjustments to the desired concentration of volatiles in
the circle system, the breathing circuit is changed to a
quasi open-circuit system, with high losses of fresh gas
and volatile anaesthetic. Furthermore, it has become
apparent that the “Zeus
®”, after working for some time
at a constant inspiratory concentration of volatiles in a
circle system, intermittently rinses the circuit system
with high fresh gas flow rates.
This may prevent unexpected increases in nitrogen in
the circle system. In a study of 44 patients undergoing
minor urological surgery, the consumption of fresh gas
and the volatile anaestheticd e s f l u r a n ew e r eh i g h e ri n
the group with the automatic closed mode of the
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®”, as compared to the mode with a special low-
flow protocol [11]. Studies in vitro and in vivo showed
that the consumption of carrier gases and volatiles can
be reduced if the “Zeus
®” is operated in an automatic
dispensing mode and if the maximum fresh gas flow
rates during the rinse phases were limited to 1-6 l/min
[12,13].
Table 3 shows the cost of inhalational anaesthetics
using different machines for the same duration of anaes-
thesia. In addition to the cost of the fresh gas and the
volatile anaesthetic acquisition, maintenance, operational
and personnel costs were also included in the calcula-
tion. This method of anaesthesia equipment cost analy-
sis allows for the comparison of different anaesthesia
devices and the discovery of potential cost savings. It
also evaluates the percent of the anaesthetic gases used
in the total cost, especially in the acquisition and main-
tenance costs, which are only a small proportion of the
overall costs of a two-hour anaesthesia. The higher
amortisation of the acquisition and maintenance costs
savings in anaesthetic gases is not possible with the cur-
rent hardware and software platforms. Contrary to our
initial assumptions, the “Zeus
®” had higher anaesthetic
gas costs with the tested hardware and software.
Limitations
This cost analysis was conducted in theatres where elec-
tive surgery was performed. The local hospital guidelines
recommend the use of low flow anaesthesia for the “Pri-
mus
®” and the automatic dosing mode when using the
“Zeus
®”. In-house guidelines recommend the use of 1%
Sevoflurane concentrations during cardiac cases when
cardiopulmonary bypass is used. To our knowledge, dur-
ing this study all the anaesthetists followed the house
intern recommendations. However, it is likely that the
unblinded anaesthetists in the Primus
® group uncon-
sciously modified their usual behaviour because of their
participation in this study to achieve reduced costs.
Therefore, this study may suggest that the attentive
anaesthetist can achieve economy equal to or better
than an automated system.
As is customary when conducting a study such as this,
we had to make assumptions for some cost categories
because there is no empirical data for these cost cate-
gories. Because the same assumptions were made for
both anaesthetic machines, a biased error would affect
both anaesthetic machines equally. The gas consump-
tion for oxygen and compressed air was taken from the
logbook of both devices. Currently, we are investigating
other anaesthetic machines at UMG. The “Zeus
®” is
receiving a software update to version 4, and the pneu-
matically operated anaesthetic machine “Leon plus”
("Heinen and Löwenstein”) has been submitted to a cost
analysis. Questions, such as whether powering
anaesthetic machines with compressed air is more eco-
nomical than powering with electricity, can be addressed
in this manner.
In summary, we conclude that it is possible to stan-
dardise the cost analysis for anaesthetic machines using
a standard method to compare acquisition, maintenance
and running costs. With the current software, the
“Zeus
®”, in the automated dosing mode, generates
higher costs per working hour than the “Primus
®” in
the manual low flow mode per working minute. Further
studies are needed to evaluate how the updated version
4 software effects the consumption of oxygen, medical
air and volatile anaesthetics in the “Zeus
®”.
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